Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
Business websites
JNJ.com
NewPharm.com
JnJMedTech.com
J&J MedTech
US • English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
Switzerland
English
Switzerland
Français
US
English
United Kingdom
English
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Careers
Life at J&J
Diversity, Equity and Inclusion
Career areas of impact
Students
Re-Ignite Program
Contract & freelance partner opportunities
Career stories
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Menu
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Careers
Life at J&J
Diversity, Equity and Inclusion
Career areas of impact
Students
Re-Ignite Program
Contract & freelance partner opportunities
Career stories
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Search Query
Submit Search
Dictate search request
Search Results
No Matching Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Search J&J.com
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Dictate search request
Listening...
Sorry, I don't understand. Please try again
1,974 results
Date
All Dates (1974)
Past 30 days (9)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (1974)
Corporate (133)
ESG (1)
Financial (289)
Global Health Equity (59)
Innovative Medicine (888)
Leadership (20)
Medical technologies (260)
Research (41)
1,974 results
Filters
Date
All Dates (1974)
Past 30 days (9)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (1974)
Corporate (133)
ESG (1)
Financial (289)
Global Health Equity (59)
Innovative Medicine (888)
Leadership (20)
Medical technologies (260)
Research (41)
Sort By:
Newest
Newest
Relevance
Oldest
July 23, 2024
Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Read more
July 22, 2024
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of real-world use that reinforce the safety and efficacy of SPRAVATO®
Read more
July 17, 2024
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024
Read more
July 17, 2024
Johnson & Johnson reports Q2 2024 results
• 2024 Second-Quarter reported sales growth of 4.3% to $22.4 Billion with operational growth of 6.6%* and adjusted operational growth of 6.5%*. Adjusted operational growth excluding COVID-19 Vaccine of 7.1%* • 2024 Second-Quarter Earnings per share (EPS) of $1.93 decreasing by 5.9% due to one-time special charges and adjusted EPS of $2.82 increasing by 10.2%* • Significant new product pipeline progress including TREMFYA IBD and subcutaneous filings, RYBREVANT subcutaneous filing, and VARIPULSE admIRE data release • Company increases Full-Year 2024 operational sales5 guidance to reflect the acquisition of Shockwave Medical • Company updates Full-Year 2024 adjusted operational EPS guidance to reflect improved performance; costs associated with recent strategic acquisitions more than offset the improvement
Read more
July 11, 2024
Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics
NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases
Read more
July 2, 2024
Johnson & Johnson Receives Approval from U.S. FDA and European Commission for SIRTURO® (bedaquiline)
Approvals supported by Phase 3 STREAM Stage 2 study results confirming favorable treatment outcomes compared to injectable-containing regimens Approvals of SIRTURO® follow accelerated approval by U.S. FDA in December 2012 and conditional approval by the EMA in March 2014
Read more
Innovative Medicine
July 2, 2024
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement
CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy
Read more
June 28, 2024
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class
First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+
Read more
June 28, 2024
CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers1 The CHMP’s recommendation is based on results from Cohort 1 of the Phase 3 THOR study, which showed a 36 percent reduction in the risk of death with erdafitinib versus chemotherapy2
Read more
June 24, 2024
Johnson & Johnson spotlights nipocalimab at FMF Congress 2024 – the first and only FcRn blocker to be studied in maternal fetal diseases
The Phase 3 AZALEA and Phase 3 FREESIA clinical studies are enrolling pregnant individuals who are at risk for severe HDFN and FNAIT These rare and potentially life-threatening alloantibody diseases affecting pregnant individuals and their fetus or newborn currently have no approved treatments
Read more
Load more
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue